Drug intelligence / Profile preview

GPN00204

Development stage: Unknown
Lead developer: Grand Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**GPN00204** is an investigational orally administered chemical drug developed by Beijing Yuanda Jiuhua Pharmaceutical for respiratory and upper-airway diseases, including acute and chronic rhinosinusitis and acute and chronic bronchitis. It has been evaluated in a Chinese Phase 1 randomized, open-label crossover study in healthy adults assessing safety, tolerability, single- and multiple-dose pharmacokinetics, and food effects. Public sources do not disclose a specific molecular target, definitive active-ingredient composition, or an assigned INN for GPN00204.

Beyond the preview

Go deeper on GPN00204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GPN00204.

Explore the full profile